Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
20.2M
-
Shares change
-
+320K
-
Total reported value, excl. options
-
$210M
-
Value change
-
+$3.87M
-
Put/Call ratio
-
0.61
-
Number of buys
-
42
-
Number of sells
-
-31
-
Price
-
$10.41
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2016
101 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2016.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.2M shares
of 236M outstanding shares and own 8.55% of the company stock.
Largest 10 shareholders include EAGLE ASSET MANAGEMENT INC (3.5M shares), Nantahala Capital Management, LLC (2.23M shares), BlackRock Fund Advisors (1.7M shares), VANGUARD GROUP INC (1.2M shares), FIRST MANHATTAN CO (1.04M shares), FMR LLC (932K shares), venBio Select Advisor LLC (832K shares), MORGAN STANLEY (815K shares), BlackRock Institutional Trust Company, N.A. (796K shares), and ACUTA CAPITAL PARTNERS, LLC (699K shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.